Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
The effect of hydroxypropyl-beta-cyclodextrin (HP-beta-CyD) on the aqueous solubility and chemical stability of O-(4-Dimethylaminoethoxycinnamoyl)fumagillol (CKD-732), a new angiogenesis inhibitor, was investigated with an aim of preparing a stable and effective parenteral formulation. The CKD-732/HP-beta-CyD inclusion complex was obtained in solid state by freeze-drying and characterized in solution by proton nuclear magnetic resonance (1H NMR). Then, the pharmacokinetic profile in rats and the in vivo tumor growth inhibitory activity in mice following the parenteral administration of aqueous CKD-732/HP-beta-CyD complex were compared to those of CKD-732.hemioxalate solution having an equivalent concentration. The aqueous solubility of CKD-732 was markedly increased by the combination of pH adjustment and HP-beta-CyD complexation through a soluble 1:1 inclusion complex formation, which was supported by NMR spectroscopy. The hydrolysis of CKD-732 following pseudo first-order kinetics was decelerated moderately but significantly in acidic and basic solutions in the presence of HP-beta-CyD. The stability of lyophilized CKD-732/HP-beta-CyD complex was also drastically improved after storage in various conditions. The intravenous pharmacokinetic profile and the subcutaneous in vivo tumor growth inhibitory activity of aqueous CKD-732/HP-beta-CyD complex were not significantly different from those of CKD-732.hemioxalate solution with the favorable reduction of irritation. These results demonstrate that the CKD-732/HP-beta-CyD complex is an attractive formulation for use in the parenteral delivery of CKD-732.
Kim
Jae-Hyun
JH
Pharmaceutical Research Labs, CKD Research Institute, Chong Kun Dang Pharm., P.O. Box 74, Chonan 330-600, South Korea. jhjaykim@dreamwiz.com
Lee
Su-Kyung
SK
Ki
Min-Hyo
MH
Choi
Won-Kyu
WK
Ahn
Soon-Kil
SK
Shin
Hee-Jong
HJ
Hong
Chung Il
CI
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy / Q000473:pathology; D002934:Cinnamates / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D003505:Cyclodextrins / Q000737:chemistry*; D003510:Cyclohexanes; D004339:Drug Compounding; D004355:Drug Stability; D004356:Drug Storage; D004852:Epoxy Compounds / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D006868:Hydrolysis; D007275:Injections, Intravenous; D051379:Mice; D019999:Pharmaceutical Solutions; D044367:Phase Transition; D051381:Rats; D017207:Rats, Sprague-Dawley; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D012995:Solubility; D013997:Time Factors; D047392:beta-Cyclodextrins
D020533:Angiogenesis Inhibitors; D002934:Cinnamates; D003505:Cyclodextrins; D003510:Cyclohexanes; D004852:Epoxy Compounds; D019999:Pharmaceutical Solutions; D012717:Sesquiterpenes; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; C487952:CKD732